Compass Therapeutics (CMPX) Share-based Compensation (2019 - 2026)

Compass Therapeutics has disclosed Share-based Compensation across 8 years of filings, most recently posting $5.1 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.1 million, up 101.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (up 20.46% YoY), and the FY2025 annual result was $8.4 million, down 2.24% from the prior year.
• Share-based Compensation came in at $5.1 million for Q1 2026 at Compass Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q1 2026 to a low of $1.0 million in Q4 2022.
• The 5-year median for Share-based Compensation is $1.6 million (2023), against an average of $2.0 million.
• Across the five-year window, Share-based Compensation tumbled 43.68% in 2025 and surged 101.79% in 2026, its largest moves.
• Compass Therapeutics' Share-based Compensation stood at $1.0 million in 2022, then jumped by 56.1% to $1.6 million in 2023, then soared by 39.88% to $2.2 million in 2024, then decreased by 18.45% to $1.8 million in 2025, then soared by 177.97% to $5.1 million in 2026.
• The last three Share-based Compensation figures came in at $5.1 million (Q1 2026), $1.8 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.